Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata

This article was originally published here

AA is an autoimmune disorder, which may result in an unpredictable hair loss on the scalp, face and other areas of the body. The FDA has provided the

The post Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply